4-氨基-2-甲基硫代噻唑-5-甲腈 | 39736-28-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 4-氨基-2-甲基硫代噻唑-5-甲腈
• 中文别名: 4-氨基-2-(甲硫基)噻唑-5-腈
• 英文名称: 2-methylmercapto-4-amino-5-cyanothiazole
• 英文别名: 4-amino-2-(methylsulfanyl)-1,3-thiazole-5-carbonitrile；4-amino-5-cyano-2-(methylsulfanyl)-1,3-thiazole；4-amino-2-(methylthio)thiazole-5-carbonitrile；4-Amino-2-(methylthio)thiazol-5-carbonitril；5-Cyano-4-amino-2-methylthio-1,3-thiazol；2-methylthio-4-amino-5-cyanothiazole；4-amino-2-methylsulfanyl-1,3-thiazole-5-carbonitrile
• CAS: 39736-28-2
• 化学式: C₅H₅N₃S₂
• mdl: MFCD00266086
• 分子量: 171.247
• InChiKey: USUFPYSYQQCDED-UHFFFAOYSA-N

物化性质

• 熔点：
  202-204°C
• 沸点：
  401.3±55.0 °C(Predicted)
• 密度：
  1.46±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  116
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 海关编码：
  2934100090
• 危险性防范说明：
  P280
• 危险性描述：
  H302,H312,H332
• 储存条件：
  室温

反应信息

• 作为反应物：
  描述：

  4-氨基-2-甲基硫代噻唑-5-甲腈 在 亚硝酸特丁酯 、 copper dichloride 作用下， 以 乙腈 为溶剂， 以83%的产率得到4-chloro-2-(methylsulfanyl)-1,3-thiazole-5-carbonitrile
  参考文献：
  名称：

  4-Bromo-2-(piperidin-1-yl)thiazol-5-yl-phenyl methanone (12b) inhibits Na+/K+-ATPase and Ras oncogene activity in cancer cells

  摘要：

  The in vitro growth inhibitory activity of 26 thiazoles (including 4-halogeno-2,5-disubtituted-1,3-thiazoles) and 5 thienothiazoles was assessed on a panel of 6 human cancer cell lines, including glioma cell lines. (4-Chloro-2-(piperidin-1-yl)thiazol-5-yl)(phenyl)methanone (12a) and (4-bromo-2-(piperidin-1-yl)thiazol-5-yl)(phenyl)methanone (12b) displayed similar to 10 times greater in vitro growth inhibitory activity than perillyl alcohol (POH), which therapeutically benefits glioma patients through the inhibition of both alpha-1 Na+/K+-ATPase (NAK) and Ras oncogene activity. The in vitro cytostatic activities (as revealed by quantitative videomicroscopy) displayed by 12a and 12b were independent of the intrinsic resistance to pro-apoptotic stimuli associated with cancer cells. Compounds 12a and 12b displayed relatively similar inhibitory activities on purified guinea pig brain preparations that mainly express NAK alpha-2 and alpha-3 subunits, whereas only compound 12b was efficacious against purified guinea pig kidney preparations that mainly express the NAK alpha-1 subunit, which is also expressed in gliomas, melanomas and non-small-cell lung cancers NSCLCs. (C) 2013 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2013.01.046
• 作为产物：
  描述：

  [cyanomethylsulfanyl(methylsulfanyl)methylidene]cyanamide 在 potassium carbonate 作用下， 反应 1.0h， 生成 4-氨基-2-甲基硫代噻唑-5-甲腈
  参考文献：
  名称：

  4-Bromo-2-(piperidin-1-yl)thiazol-5-yl-phenyl methanone (12b) inhibits Na+/K+-ATPase and Ras oncogene activity in cancer cells

  摘要：

  The in vitro growth inhibitory activity of 26 thiazoles (including 4-halogeno-2,5-disubtituted-1,3-thiazoles) and 5 thienothiazoles was assessed on a panel of 6 human cancer cell lines, including glioma cell lines. (4-Chloro-2-(piperidin-1-yl)thiazol-5-yl)(phenyl)methanone (12a) and (4-bromo-2-(piperidin-1-yl)thiazol-5-yl)(phenyl)methanone (12b) displayed similar to 10 times greater in vitro growth inhibitory activity than perillyl alcohol (POH), which therapeutically benefits glioma patients through the inhibition of both alpha-1 Na+/K+-ATPase (NAK) and Ras oncogene activity. The in vitro cytostatic activities (as revealed by quantitative videomicroscopy) displayed by 12a and 12b were independent of the intrinsic resistance to pro-apoptotic stimuli associated with cancer cells. Compounds 12a and 12b displayed relatively similar inhibitory activities on purified guinea pig brain preparations that mainly express NAK alpha-2 and alpha-3 subunits, whereas only compound 12b was efficacious against purified guinea pig kidney preparations that mainly express the NAK alpha-1 subunit, which is also expressed in gliomas, melanomas and non-small-cell lung cancers NSCLCs. (C) 2013 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2013.01.046

文献信息

• SUBSTITUTED IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES
  申请人：Siegel Stephan

  公开号：US20100113441A1

  公开（公告）日：2010-05-06

  The invention relates to substituted imidazopyrimidines and triazolopyrimidines, to methods for the production thereof, and to the use of same for producing medicaments for the treatment and/or prophylaxis of diseases, especially haematological diseases, preferably leucopenia and neutropenia.

  本发明涉及取代的咪唑[嘧啶]和三唑[嘧啶]，及其生产方法，以及用于生产用于治疗和/或预防疾病，特别是血液病，尤其是白血球减少症和粒细胞减少症的药物的应用。
• [EN] AZOLOPYRIDINE AND AZOLOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF<br/>[FR] COMPOSÉS D'AZOLOPYRIDINE ET D'AZOLOPYRIMIDINE ET MÉTHODES D'UTILISATION ASSOCIÉES
  申请人：AMBIT BIOSCIENCES CORP

  公开号：WO2012030924A1

  公开（公告）日：2012-03-08

  Provided herein are azolopyridine and azolopyrimidine compounds for treatment of JAK kinase mediated diseases, including JAK2 kinase-, JAK3 kinase- or TYK2 kinase-mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.

  本文提供了用于治疗JAK激酶介导疾病的咪唑吡啶和咪唑吡啶化合物，包括JAK2激酶、JAK3激酶或TYK2激酶介导的疾病。还提供了包含这些化合物的药物组合物以及使用这些化合物和组合物的方法。
• SUBSTITUTED IMIDAZO- AND TRIAZOLOPYRIMIDINES, IMIDAZO- AND PYRAZOLOPYRAZINES AND IMIDAZOTRIAZINES
  申请人：Siegel Stephan

  公开号：US20110144131A1

  公开（公告）日：2011-06-16

  The invention relates to substituted imidazo- and triazolopyrimidines, imidazo- and pyrazolopyrazines and imidazotriazines and processes for their preparation, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, in particular of hematological disorders, preferably of leukopenias and neutropenias.

  这项发明涉及取代咪唑基和三唑基嘧啶、咪唑基和吡唑基吡嗪以及咪唑基三嗪，以及它们的制备方法，以及它们用于制造用于治疗和/或预防疾病的药物，特别是血液疾病，最好是白细胞减少症和中性粒细胞减少症。
• SUBSTITUTED 4-(SELENOPHEN-2(OR-3)-YLAMINO)PYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF
  申请人：KASINA LAILA INNOVA PHARMACEUTICALS PRIVATE LIMITED

  公开号：US20130266563A1

  公开（公告）日：2013-10-10

  Selenophene compounds of formula (I) are described herein. In the compounds of Formula (I), ring A is a 6-membered aromatic fused ring, optionally containing one, two or three nitrogen atoms; a 5-membered heteroaromatic fused ring; or a mono- or bicyclic saturated heterocyclic fused ring having at least one ring member selected from the group consisting of N, O, S, SO and SO 2 ; Y in ring B is nitrogen or substituted carbon; X is NR 6 , O, S, S(O), or S(O) 2 . R 1 , R 2 , R 3 , R 4 , and R 6 are defined in the specification. Selenophene compounds of formula (I) may be used in methods of treating cell proliferative disorders, particularly cancer. Pharmaceutical compositions containing selenophene compounds of formula (I) may be used for treatment, inhibition, or control of cancer.

  Selenophene化合物的化学式（I）在此描述。在化合物的化学式（I）中，环A是一个6元芳香融合环，可选地含有一个、两个或三个氮原子；一个5元杂芳融合环；或者至少有一个环成员选自N、O、S、SO和SO2的单环或双环饱和杂环融合环；环B中的Y是氮或取代碳；X是NR6、O、S、S（O）或S（O）2。R1、R2、R3、R4和R6在规范中有定义。化学式（I）的Selenophene化合物可用于治疗细胞增殖紊乱的方法，特别是癌症。含有化学式（I）的Selenophene化合物的药物组合物可用于治疗、抑制或控制癌症。
• Beiträge zum reaktionsverhalten von derivaten der imidodithiokohlensäure—I
  作者：W. Walek、M. Pallas、M. Augustin

  DOI：10.1016/s0040-4020(01)93783-4

  日期：1976.1

  The reaction of potassium-alkyl-cyanoimidodithiocarbonate 1 with α-CH-acid halo compounds to 4-aminothiazoles 3, with monochloramine to 3-amino-1,2,4-thiadiazoles 5, and with α-halocarboxylic acid anilides to 4-thiazolidinones derivatives 12 is described. Characteristics of mass- and IR-spectra of the synthesized compounds are discussed.

  烷基烷基氰基氨基二硫代碳酸钾1与α-CH-酸卤代化合物反应成4-氨基噻唑3，一氯胺反应生成3-氨基-1,2,4-噻二唑5，与α-卤代羧酸酐反应成4-噻唑烷酮描述了导数12。讨论了合成化合物的质谱和红外光谱特征。